pirenzepine has been researched along with Kidney Diseases in 3 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cadmium (Cd) toxicity was produced in male rats to study the role of cholinoceptors in Cd-induced endothelial dysfunction." | 1.32 | Involvement of cholinoceptors in cadmium-induced endothelial dysfunction. ( Alkan, Z; Bilgen, I; Cirrik, S; Edremitlioğlu, M; Oner, G, 2003) |
| " Plasma concentrations remained in the therapeutic range and the dosage regimen was well tolerated." | 1.28 | Steady-state intravenous pharmacokinetics of pirenzepine in patients with hepatic insufficiency and combined renal- and hepatic insufficiency. ( Bozler, G; Krakamp, B; Leidig, P; Schmitz, R; Tanswell, P; Vogel, H, 1989) |
| " Pirenzepine renal clearance, total clearance and terminal (dominant) half-life were found to be correlated with the creatinine clearance (CLCR), but this was not the case for the volume of distribution and the nonrenal clearance." | 1.28 | Steady-state intravenous pharmacokinetics of pirenzepine in patients with differing degrees of renal dysfunction. ( Bozler, G; Krakamp, B; Tanswell, P; Vogel, H, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilgen, I | 1 |
| Oner, G | 1 |
| Edremitlioğlu, M | 1 |
| Alkan, Z | 1 |
| Cirrik, S | 1 |
| Krakamp, B | 2 |
| Tanswell, P | 2 |
| Leidig, P | 1 |
| Vogel, H | 2 |
| Schmitz, R | 1 |
| Bozler, G | 2 |
3 other studies available for pirenzepine and Kidney Diseases
| Article | Year |
|---|---|
Involvement of cholinoceptors in cadmium-induced endothelial dysfunction.
Topics: Acetylcholine; Administration, Oral; Animals; Aorta, Thoracic; Atropine; Cadmium; Calcimycin; Dose-R | 2003 |
Steady-state intravenous pharmacokinetics of pirenzepine in patients with hepatic insufficiency and combined renal- and hepatic insufficiency.
Topics: Adult; Aged; Chronic Disease; Female; Half-Life; Humans; Kidney Diseases; Liver Cirrhosis; Liver Dis | 1989 |
Steady-state intravenous pharmacokinetics of pirenzepine in patients with differing degrees of renal dysfunction.
Topics: Adolescent; Adult; Creatinine; Female; Half-Life; Humans; Kidney Diseases; Male; Metabolic Clearance | 1989 |